Ozempic Gastroparesis Settlement: Statute of Limitations for Ozempic in Massachusetts

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Occupational Exposure Concerns

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy context has empowered individuals to engage with complex health topics, from chronic disease management to pharmaceutical innovations. Within this broad framework, the public has become increasingly aware of both the benefits and potential risks associated with widely prescribed medications. One such medication, Ozempic, originally developed for type 2 diabetes management, has garnered significant attention for its efficacy and expanding applications. As the health information landscape evolves, a natural progression emerges from general awareness to specific, real-world concerns. This transition is particularly relevant when considering occupational or environmental exposure scenarios. In the context of mass production, workers involved in the manufacturing, handling, or packaging of pharmaceutical compounds may face distinct exposure considerations. The shift from a general health consumer perspective to an occupational focus requires careful examination of how prolonged or concentrated contact with active ingredients, such as those in Ozempic, could influence health outcomes. This pivot does not assert causal mechanisms but rather acknowledges the need to evaluate potential risks within industrial settings, where exposure parameters differ markedly from therapeutic use.

Bridging to Clinical Evidence: Ozempic and Gastrointestinal Adverse Reactions

Building upon the established heritage of health science communication, we now turn to the clinical evidence linking Ozempic (semaglutide) to gastrointestinal adverse reactions, including gastroparesis. Gastroparesis is a chronic disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may result in malnutrition, dehydration, and metabolic disturbances. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacology involves slowing gastric emptying, which contributes to its glucose-lowering effects but also underlies many gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients with type 2 diabetes mellitus include nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal symptoms, which aligns with the mechanistic pathway linking GLP-1 receptor agonists to delayed gastric emptying and potential gastroparesis.

Mechanistic Pathway and Risk Context for Gastroparesis

The mechanistic pathway connecting Ozempic to gastroparesis involves the drug's effect on gastric motility. GLP-1 receptor agonists slow gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to prolonged retention of gastric contents. In susceptible individuals, this effect may become pathological, resulting in gastroparesis. The timeline between exposure and documented harm can vary; symptoms often emerge during dose escalation, but chronic use may lead to persistent gastric dysfunction. Patients who develop severe or prolonged gastrointestinal symptoms should be evaluated for gastroparesis. Regarding risk anchors, the adequacy of warnings for Ozempic and gastroparesis is a critical consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not specifically list gastroparesis as a known adverse effect. The label notes that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported and that caution is needed in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may be relevant in settlement-related considerations for affected patients. Patients who developed gastroparesis after using Ozempic may argue that the manufacturer failed to adequately warn about this risk, particularly given the known mechanism of delayed gastric emptying.

Statute of Limitations for Ozempic Gastroparesis Claims in Massachusetts

Settlement-related considerations for affected patients in Massachusetts involve the statute of limitations, which governs the time frame within which a lawsuit must be filed. In Massachusetts, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date of injury or from the date when the injury was discovered or reasonably should have been discovered. For gastroparesis allegedly caused by Ozempic, the timeline between exposure and documented harm is crucial. Patients who experienced symptoms during dose escalation or after prolonged use should document the onset of symptoms, the date of diagnosis, and the relationship to Ozempic use. The statute of limitations may begin to run when the patient knew or should have known that the injury was caused by the drug. Therefore, patients should seek legal advice promptly to ensure their claims are filed within the applicable time frame. In summary, the evidence demonstrates a clear association between Ozempic use and gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, which are consistent with the clinical presentation of gastroparesis. The mechanistic pathway involving delayed gastric emptying supports a plausible link between Ozempic and gastroparesis. The adequacy of warnings is a key risk factor, as the label does not specifically mention gastroparesis. Patients in Massachusetts who have developed gastroparesis after using Ozempic should be aware of the statute of limitations and consider legal consultation to evaluate their options for settlement or litigation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date of injury or from the date when the injury was discovered or reasonably should have been discovered. For gastroparesis allegedly caused by Ozempic, patients should document the onset of symptoms, the date of diagnosis, and the relationship to Ozempic use. The statute of limitations may begin to run when the patient knew or should have known that the injury was caused by the drug. Therefore, patients should seek legal advice promptly to ensure their claims are filed within the applicable time frame.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying, which can lead to gastrointestinal adverse reactions such as nausea, vomiting, and abdominal pain. In susceptible individuals, this effect may become pathological, resulting in gastroparesis. Clinical trials have shown a dose-dependent increase in gastrointestinal symptoms, and the prescribing information does not specifically list gastroparesis as a known adverse effect, which may be relevant in legal claims regarding inadequate warnings.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.